Completed PHASE3 INTERVENTIONAL 2-arm NCT00735761

Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients

A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients

Sponsor: Medivir

Conditions Herpes Labialis

Interventions Acyclovir in ME-609 vehicle (5% acyclovir) ME-609

Updated 4 times since 2017 Last updated: Aug 14, 2008 Started: Dec 31, 2006 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00735761, this PHASE3 trial focuses on Herpes Labialis and remains completed. Sponsored by Medivir, it has been updated 4 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medivir

Data source: Medivir

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.